18th International Conference on Alzheimer’s Drug Discovery

18th International Conference on Alzheimer’s Drug Discovery

September 11-12, 2017

 

Hyatt Regency
Jersey City, NJ

Save the date!

This annual conference brings together academic and industry scientists intent on accelerating the development of innovative treatments for Alzheimer's disease and related dementias. The ADDF's funded investigators and top-level scientists in the field will present on their current research progress and stimulate discussion. The conference offers ample opportunity for collaboration and partnering.

Alzheimer's Drug Discovery Foundation

Seventh Annual
Great Ladies Luncheon & Fashion Show

Seventh Annual Great Ladies Luncheon & Fashion Show

April 26, 2017

10:45 am | Symposium

12:00 pm | Luncheon

 

The Ritz Carlton
Washington, DC

The Alzheimer's Drug Discovery Foundation and Neiman Marcus Mazza Gallerie present the Seventh Annual Great Ladies Luncheon & Fashion Show. At this year's luncheon, we are thrilled to present the Great Ladies Award to Sally Quinn, esteemed author and journalist, for her contributions to the fight against Alzheimer's disease. Guests at the event will enjoy a rare runway show by Italian designer Brunello Cucinelli.

The Great Ladies Luncheon is generously underwritten by Elise Lefkowitz.

For more information, please contact rsvp@alzdiscovery.org.

Alzheimer's Drug Discovery Foundation

Sip & Shop at J.McLaughlin

Sip & Shop at J.McLaughlin

February 23, 2017

5:00 - 7:00 pm

 

J.McLaughlin
Palm Beach, FL

Over the President's Day holiday, join us at classic American clothier J.McLaughlin's Palm Beach location for light bites and drinks. 

J.McLaughlin will donate 15% of all sales during the event to benefit the ADDF and our mission to accelerate drugs to prevent, treat, and cure Alzheimer’s and related dementias.

Alzheimer's Drug Discovery Foundation

11th Annual
Drug Discovery for Neurodegeneration Conference

11th Annual Drug Discovery for Neurodegeneration Conference

February 12-14, 2017

 

DoubleTree by Hilton Hotel San Diego – Mission Valley
San Diego, CA

An Educational Course on Translating Research into Drugs

Designed as a comprehensive course, this didactic conference educates scientists on the processes of translating basic research into novel therapies and leaves participants with a strong knowledge base and relevant resources to address the associated barriers and challenges in developing a drug. The programs also highlight case studies of small molecule and biologics programs at different stages of development aimed at tackling challenging CNS targets relevant to neurodegeneration. The program includes sessions for networking, partnering/mentoring, and posters presented by young investigators.

Register by January 12, 2017 and save up to $100.

Young Investigator Scholarships

The ADDF offers 30 Young Investigator Scholarships to graduate students, postdoctoral fellows, and physician-scientists. Each scholarship provides a single registration to attend the conference, an opportunity to present a poster, and name recognition in the program and on the conference website.
Application Deadline: December 9, 2016


Get Updates on the ADDF's Upcoming Conferences and Meetings

Sign up to receive news by email.

Alzheimer's Drug Discovery Foundation

Seventh Annual
Fall Symposium & Luncheon

Seventh Annual Fall Symposium & Luncheon

November 14, 2016

10:30 am | Symposium

12:00 pm | Luncheon

Business Attire

 

The Pierre
New York, NY

Join us for the Seventh Annual Fall Symposium & Luncheon "Hope on the Horizon," hosted by Emmy Award-winning journalist Paula Zahn. At this year's luncheon, we are thrilled to honor philanthropist and President of Advance Publications, Inc., Donald E. Newhouse, for his commitment to dementia research. The morning symposium will feature Howard Fillit, MD, Founding Executive Director and Chief Science Officer of the ADDF, and a panel of leading scientists discussing the connections between Alzheimer's and other diseases such as frontotemporal dementia and Parkinson's and the drugs currently in clinical trials that hold promise for multiple diseases. 

All proceeds from Hope on the Horizon support the ADDF's mission to accelerate the discovery and development of drugs to prevent, treat, and cure Alzheimer’s and related diseases.

Symposium Panelists

Sandra E. Black, OC, O.Ont, MD, FRCP(C)
Brill Chair in Neurology, Department of Medicine, Sunnybrook Health Sciences Center & University of Toronto
Executive Director, Toronto Dementia Research Alliance

Carlos Buesa, PhD
CEO, Oryzon Genomics

Michela Gallagher, PhD
Krieger-Eisenhower Professor, Johns Hopkins University with joint appointments in Neuroscience and Psychology Departments

Edward D. Huey, MD
Assistant Professor of Psychiatry and Neurology, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, The Gertrude H. Sergievsky Center, Columbia University

EVENT SPONSORS


  • Estee Lauder Companies
  • Staples Business Advantage
  • Eli Lilly

LEADERSHIP


Executive Chairs

  • Renée and Robert Belfer
  • Nancy and Mel Goodes
  • The Lauder Foundation — Leonard & Judy Lauder Fund
  • Jo Carole and Ronald S. Lauder
  • Samuel I. Newhouse Foundation, Inc.
  • Liz and Randal Sandler

Honorary Chairs

  • Bonnie Pfeifer Evans
  • Alice Shure

Co-Chairs

  • The Altec-Styslinger Foundation,
        Jennifer and Mark Styslinger
  • Eli Lilly and Company
  • The Estée Lauder Companies Inc.
  • Julie and Phil Geier
  • Howard Kaneff
  • Mitchell Kaneff
  • Susan Lloyd
  • Staples Business Advantage

Vice Chairs

  • Arcade Beauty
  • Colliers International NY LLC
  • Ehrenkranz Partners
  • Liz and George Krupp
  • Neiman Marcus Group
  • Laura and Stephen Toma

Host Committee

  • Renée and Robert Belfer
  • Carole Cooper and Richard Leibner
  • Joel S. Ehrenkranz
  • Julie and Phil Geier
  • David Gerson
  • US Senator Kirsten Gillibrand
  • Nancy and Mel Goodes
  • Deborah and Peter Krulewitch
  • Liz and George Krupp
  • William P. Lauder
  • Bonnie Englebardt Lautenberg
  • Larry Leeds
  • Susan and Tom Lowder
  • Carlyn S. McCaffrey
  • Laura and Stephen Toma
  • Carol and Michael Weisman
  • Jan Willinger and Robert Spiegel
  • Paula Zahn
Alzheimer's Drug Discovery Foundation

ADDF Exhibiting at
The Society for Neuroscience Annual Meeting

ADDF to Exhibit at the Society for Neuroscience Annual Meeting

November 12-16, 2016

 

San Diego Convention Center
San Diego, CA

Come visit the ADDF team at the 46th Annual SfN Meeting in Booth 3800! Learn more about our upcoming conferences, grant opportunities, ADDF ACCESS program, and much more!


Get Updates on Where the ADDF will be Next

Sign up to receive news by email.

Alzheimer's Drug Discovery Foundation

2016 TCS New York City Marathon

2016 TCS New York City Marathon

November 6, 2016

 


New York, NY

The ADDF was once again selected as an official charity partner for the TCS New York City Marathon. Donations to our team, Runners for Alzheimer's Research, directly support research into new treatments for this devastating disease. In 2015, our eight team members raised nearly $85,000, far surpassing their goal. 

Though we are making great strides, Alzheimer's remains the only top 10 cause of death in the U.S. that can't be prevented, cured, or even slowed. By supporting our team, Runners for Alzheimer's Research, you will help us further our mission to rapidly accelerate the discovery of drugs to prevent and treat Alzheimer's disease.

Read about why one team member, Ernest Scheyder, is running for the ADDF.

Please note that the Alzheimer's Drug Discovery Foundation is no longer accepting applications for invitational entry into the 2016 TCS New York City Marathon. Official qualified participants who are already entered in the 2016 TCS New York City Marathon and wish to raise funds for the ADDF may still do so by contacting Jessica Cavanaugh at jcavanaugh@alzdiscovery.org.

Alzheimer's Drug Discovery Foundation

17th International Conference on Alzheimer’s Drug Discovery

17th International Conference on Alzheimer’s Drug Discovery

September 12-13, 2016

 

Hyatt Regency
Jersey City, NJ

This annual conference brings together academic and industry scientists intent on accelerating the development of innovative treatments for Alzheimer’s disease and related dementias. The ADDF's funded investigators and top-level scientists in the field will present on their current research progress and stimulate discussion. The conference offers ample opportunity for collaboration and partnering.

This Year's Speakers

• Dirk Beher, Aceneuron
• Elizabeth Bradshaw, Brigham and Women's Hospital
• Carol Colton, Duke University Medical Center
• Mari DeMarco, University of British Columbia
• Pontus Forsell, AlzeCure Foundation
• Michael Gold, PPD
• Atticus Hainsworth, St. George, University of London
• Ihab Hajjar, Emory University
• Mansuo Hayashi, Eli Lilly and Company
• Lawrence Honig, Columbia University
• Edward Huey, Columbia University
• Berkley Lynch, Rodin Therapeutics
• Alexandros Makriyannis, Northeastern University
• Yukari Perrella, Yuma Therapeutics
• Jerri Rook, Vanderbilt Center of Neuroscience Drug Discovery
• Sharon Rosenzweig-Lipson, AgeneBio
• Stephen Salton, Icahn School of Medicine at Mount Sinai
• Grace Stutzmann, Rosalind Franklin University of Science and Medicine
• Paul Thompson, University of Massachusetts
• Raymond Scott Turner, Georgetown University
• Shijun Zhang, Virginia Commonwealth University
• Danna Zimmer, University of Maryland School of Medicine


Get Updates on the ADDF's Upcoming Conferences and Meetings

Sign up to receive news by email.

Alzheimer's Drug Discovery Foundation

Sip & Shop at J.McLaughlin

Sip & Shop at J.McLaughlin

September 8, 2016

6:00 - 8:00 pm

 

J.McLaughlin
New York, NY

Join us for light bites and drinks while you shop the Fall 2016 Collection from classic American clothier J.McLaughlin at its 1004 Lexington Avenue location. 

J.McLaughlin will donate 15% of all sales during the event to benefit the ADDF and our mission to accelerate drugs to prevent, treat, and cure Alzheimer’s and related dementias.

For those unable to attend, the store will donate for purchases made all weekend when you mention the ADDF.

Alzheimer's Drug Discovery Foundation

Surgery and Cognition:
Delirium, Cognitive Decline, and Opportunities to Protect the Brain

Surgery and Cognition: Delirium, Cognitive Decline, and Opportunities to Protect the Brain

June 21, 2016

8:00 am - 5:00 pm

 

The New York Academy of Sciences
New York, NY

Surgery helps millions of Americans overcome illness and live longer, healthier lives. Yet for many patients, surgery can also lead to delirium, cognitive decline, and perhaps even a higher long-term risk of dementia. These risks are poorly understood and often underrecognized in the clinic. The level of risk to a patient depends on the individual and the surgery. For example, delirium is experienced in 15–80% of surgical patients who, in turn, may have a higher risk of long-term cognitive and functional decline.

This one-day meeting, presented by the Alzheimer's Drug Discovery Foundation and the Brain Dysfunction Discussion Group, will convene leading scientists to discuss the challenges and opportunities to create biomarkers and therapeutics for these vulnerable patients.

Can't attend in person? Join the meeting online by registering for the webinar.

Alzheimer's Drug Discovery Foundation

Nexus of Alzheimer’s, Related Dementias & Cancer

Nexus of Alzheimer’s, Related Dementias & Cancer

May 25, 2016

8:00 am - 5:00 pm

 

Park Hyatt
Washington, D.C.

This meeting, organized by the Alzheimer's Drug Discovery Foundation and Alzheimer’s Association, delved into the biological underpinnings that may explain the linkage between cancer and Alzheimer’s. It also provided new avenues for drug discovery.

Sessions focused on current insights from epidemiology, mechanistic and genetic links between cancer and Alzheimer's disease, and therapeutic implications. The goal was to identify specific research questions and linkages needed to advance treatments for Alzheimer's.

Alzheimer's Drug Discovery Foundation

1st European Drug Discovery for Neurodegeneration Conference

1st European Drug Discovery for Neurodegeneration Conference

May 15-17, 2016

 

The Danubius Health Spa Resort
Budapest, Hungary

We are hosting our first European conference on Drug Discovery for Neurodegeneration: An Educational Course on Translating Research into Drugs which is based on the ADDF’s annual US-based Drug Discovery for Neurodegeneration conference, which was established in 2007 to meet the following objectives:

  1. Train a cadre of interdisciplinary scientists in the principles of drug discovery for neurodegenerative disease (NDD)

  2. Provide a platform to exchange ideas, knowledge and resources about drug discovery for NDD

  3. Stimulate preclinical research in the discovery and testing of novel compounds aimed at the prevention and treatment of NDD

  4. Build public-private partnerships that will accelerate drug discovery for NDD

This didactic conference will educate scientists on the processes of translating basic research into novel therapies and will leave participants with a strong knowledge base and relevant resources to address the associated barriers and challenges in developing a drug. The program will also highlight case studies of small molecule and biologics programs at different stages of development aimed at tackling challenging CNS targets relevant to NDD.


Get Updates on the ADDF's Upcoming Conferences and Meetings

Sign up to receive news by email.

Alzheimer's Drug Discovery Foundation

Tenth Annual
Connoisseur’s Dinner

Tenth Annual Connoisseur’s Dinner

April 28, 2016

6:00 pm | Cocktails

7:30 pm | Dinner

Black Tie

 

Sotheby's, 1334 York Avenue
New York, NY

Join us for our annual gala, which will honor Ronald S. Lauder for his visionary leadership in supporting new treatments for Alzheimer's. The Connoisseur's Dinner will feature an exclusive preview of Sotheby’s Spring Impressionist, Modern and Contemporary Art Sale, with wine pairings presented by Sotheby’s and a live Fund a Scientist Auction conducted by Jamie Niven.

EVENT SPONSORS


  • Avenue Magainze
  • Estee Lauder Companies
  • EY
  • JP Morgan
  • Macy's Inc
  • Northern Trust
  • Nucor Construction Corp
  • Pfizer
  • Sotheby's
  • Tishman Speyer

LEADERSHIP


Executive Chairs

  • Anonymous
  • The Lauder Foundation
    — The Leonard and Judy Lauder Fund
  • The Ronald and Jo Carole Lauder Foundation
  • Sir Evelyn and Lady Lynn Forester de Rothschild
  • Mr. and Mrs Randal B. Sandler

Co-Chairs

  • Mr. and Mrs. Robert J. Appel
  • Blavatnik Family Foundation
  • The Calvin Klein Family Foundation
  • Ms. Nancy Corzine
  • Mr. and Mrs. Melvin R. Goodes
  • Mrs. Judy Glickman Lauder
    and all of the Glickman Family
  • Mr. and Mrs. Chris Reyes

Vice-Chairs

  • Ms. Carol Seabrook Boulanger
  • Ms. Rose Marie Bravo
  • Ms. Caryn Clayman
  • EY
  • J.P. Morgan
  • Mr. and Mrs. Gary Lauder
  • Mrs. Bonnie Englebardt Lautenberg
  • Macy's and Bloomingdale's
  • Mr. and Mrs. Howard Marks
  • Mr. Donald E. Newhouse
  • The Northern Trust Company
  • Nucor Construction Corp.
  • Pfizer Inc.
  • The Ralph and Ricky Lauren Family Foundation
  • Mr. and Mrs. Olivier Reza
  • Ms. Lois Robbins and Mr. Andrew Zaro
  • Mr. and Mrs. Peter J. Solomon
  • Sotheby's
  • Mr. and Mrs. Andrew Tisch
  • Tishman Speyer
  • Thomas H. Lowder Family Foundation
  • Mr. and Mrs. Michael Weisman
  • Ms. Wendy Wilson and Mr. Ronald Dickerman
Alzheimer's Drug Discovery Foundation

Sixth Annual
Great Ladies Luncheon & Fashion Show

Sixth Annual Great Ladies Luncheon & Fashion Show

April 13, 2016

10:45 am | Scientific Presentation

12:00 pm | Fashion Show & Luncheon

2:00 pm | Oscar de la Renta Trunk Show

Business Attire

 

The Ritz Carlton
Washington, DC

The Alzheimer’s Drug Discovery Foundation and Neiman Marcus Mazza Gallerie present the Sixth Annual Great Ladies Luncheon & Fashion Show, honoring Trish and George Vradenburg for their contributions to the fight against Alzheimer's disease. Guests at the event, hosted by Chris Wallace, will enjoy a special presentation of Oscar de la Renta's Fall 2016 Collection.

The Great Ladies Luncheon is generously underwritten by Elise Lefkowitz. For more information, please contact Jessica Cavanaugh at jcavanaugh@alzdiscovery.org or 212.901.8011.

EVENT SPONSORS


  • Estee Lauder Companies
  • FedEx
  • Neiman Marcus
  • Oscar de la Renta

LEADERSHIP


Executive Chairs

  • Elise and Marc Lefkowitz
  • Leonard A. Lauder
  • Ronald S. Lauder

Co-Chairs

  • The Estée Lauder Companies, Inc.
  • Thomas Pheasant

Vice-Chairs

  • Shelley and Robby Banks
  • Liz Dubin
  • FedEx
  • Elizabeth W. Galvin
  • Nancy and Mel Goodes
  • Eileen Shields-West
  • Lorraine Wallace

Ladies Executive Committee

Co-Chaired by: Laurie Monahan and Lorraine Wallace

Lise Adkins
Tina S. Alster, MD
Amy Baier
Shelley Banks
Lisa Brandt Beek
Wilma Bernstein
Faith Bobrow
Evelyn Brandt
Jill and Dan Brigati
Nancy Taylor Bubes
Buffy Cafritz
Lynda Camalier
Connie Carter
Lynda Carter
Sharon Collins Casey
Kristin Rae Cecchi
Marcella Cohen
Meryl Comer
Debbie Dingell
Martha Dippell
Nancy Duber
Liz Dubin
Deborah L. Epstein
Samia Farouki
Ann Free
Debra Friedmann
Elizabeth W. Galvin
Alma Gildenhorn

Beth Glassman
Nancy and Mel Goodes
Ann Hand
Raeanne Hytone
Cindy Jones
Mary Ann Kibarian
Diana Kogan
Dana Landow
Willee Lewis
Marlene A. Malek
Dobra and Bennett Marshall
JoAnn and John Mason
Barbara McInerney
Andrea Mitchell
Melanie and Larry Nussdorf
Mary Ourisman
Thomas Pheasant
Ginger Pickle
Patricia Bennett Sagon
Marilou Sanford
Eileen Shields-West
Bonnie Staffier
Shawn Taylor
Anne Hatfield Weir
Dr. Tina B. West
Cathy Merrill Williams
Carol Gildenhorn Winer
Delores Wolf

Alzheimer's Drug Discovery Foundation

10th Annual Drug Discovery for Neurodegeneration Conference

10th Annual Drug Discovery for Neurodegeneration Conference

March 6-8, 2016

 

Miami Beach Resort
Miami Beach, FL

Designed as a comprehensive course, this didactic conference educates scientists on the processes of translating basic research into novel therapies and leaves participants with a strong knowledge base and relevant resources to address the associated barriers and challenges in developing a drug. The programs also highlight case studies of small molecule and biologics programs at different stages of development aimed at tackling challenging CNS targets relevant to neurodegeneration. The program includes sessions for networking, partnering/mentoring, and posters presented by young investigators.


Get Updates on the ADDF's Upcoming Conferences and Meetings

Sign up to receive news by email.

Alzheimer's Drug Discovery Foundation

New York City Drug Discovery Conference

New York City Drug Discovery Conference

February 12, 2016

 

Apella, Event Space at Alexandria Center
New York, NY

In 2015, we hosted our first New York City Drug Discovery Conference: An Educational Course on Translating Research into Drugs. This one-day meeting educated scientists from varying disciplines on the processes of translating basic research into novel therapies and left them with a strong knowledge base and relevant resources to address the associated barriers and challenges in developing a drug. Holding this meeting in NYC helped to foster the city’s growing biotechnology community, educate academic scientists, and stimulate new partnerships. 

This meeting was based on the ADDF’s annual Drug Discovery for Neurodegeneration Conference, which was established in 2007 to: (1) Train a cadre of interdisciplinary scientists in the principles of drug discovery; (2) Provide a platform to exchange ideas, knowledge and resources about drug discovery; (3) Stimulate preclinical research in the discovery and testing of novel compounds aimed at prevention and treatment; and (4) Build public-private partnerships that will accelerate drug discovery.

Slideshow Presentations by Guest Speakers

Howard Fillit, MD, ADDF

Shari Coulter Ford, MBA, Partnership Fund for New York City

Robert J. DeVita, PhD, Mount Sinai

J. Fraser Glickman, PhD, The Rockefeller University

Sarah J. Schlesinger, MD, The Rockefeller University

Alzheimer's Drug Discovery Foundation

A play by Colman Domingo
Dot

DOT, a play by Colman Domingo

February 9, 2016

6:00 pm

Tickets $200

 

Vineyard Theatre
New York, NY

Join us for DOT, a play about a family dealing with dementia. Guests will enjoy a special cocktail reception before the show and an exclusive Q & A following the performance with Howard Fillit, MD, Director Susan Stroman, and the cast of Dot. All proceeds from the evening's ticket sales support the ADDF and our mission to accelerate treatment for Alzheimer's disease.

Family matriarch Dotty and her three adult children gather for the holidays with more than exchanging presents on their minds. As Dotty struggles to navigate life with dementia, her children fight to balance care for their mother and care for themselves. A testament to the enduring bonds of family, this hilarious and moving new play by Colman Domingo (author of Vineyard’s A Boy and His Soul and Tony Award nominee for his role in Vineyard’s production of The Scottsboro Boys) grapples unforgettably with aging parents, midlife crises, and the heart of an inner city neighborhood. It's directed by Tony Award winner Susan Stroman, who returns to The Vineyard after her ground-breaking work on The Scottsboro Boys.

Alzheimer's Drug Discovery Foundation

Sixth Annual
Fall Symposium & Luncheon

Sixth Annual Fall Symposium & Luncheon

November 9, 2015

 

The Pierre
New York, NY

 

Luncheon Host: Paula Zahn 


Margaret and Daniel Loeb received The Charles Evans Award at our Sixth Annual Fall Symposium & Luncheon “Hope on the Horizon” at The Pierre in New York City. Thanks to the generosity of our donors, the Symposium & Luncheon raised more than $1 million, the most in the event’s history. All proceeds support our mission to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer’s disease.  

Following the awards ceremony, Emmy Award-winning journalist Paula Zahn conducted a thought-provoking interview with Howard Fillit, MD, Founding Executive Director and Chief Science Officer of the ADDF, and Richard Mohs, PhD, Retired Vice President for Neuroscience Early Clinical Development & Distinguished Research Fellow, Eli Lilly and Company. Dr. Fillit and Dr. Mohs discussed the enormous progress that has already been made and explained the potential of new treatments for Alzheimer’s currently in clinical trials.

The morning Symposium by Dr. Fillit, “Conquering Alzheimer’s Disease,” was opened by Ronald S. Lauder, who told the riveted audience: “Hope really is on the horizon. Thanks to the extraordinary efforts of the ADDF and the scientists it funds across the globe, we’re closer than ever to conquering this disease.” 


©Patrick McMullan
Photo - Sean Zanni/PMC

Alzheimer's Drug Discovery Foundation

2015 TCS New York City Marathon

2015 TCS New York City Marathon

November 1, 2015

 


New York, NY

The Alzheimer's Drug Discovery Foundation is thrilled to be an official charity partner of the 2015 TCS New York City Marathon.

Our team of eight "Runners for Alzheimer’s Research" are passionate about finding a cure for Alzheimer’s disease. While more than 5.5 million Americans are currently living with Alzheimer’s (the third-leading cause of death in the United States) research for a cure remains underfunded.

By supporting our team, you will help us further our mission to rapidly accelerate the discovery of drugs to prevent, treat and cure Alzheimer's disease.

DONATE
Alzheimer's Drug Discovery Foundation

ADDF to Exhibit at
The Society for Neuroscience Annual Meeting

ADDF at the Society for Neuroscience Annual Meeting

October 17-21, 2015

 

Hyatt Regency Chicago
Chicago, IL

The ADDF team was at booth 2028 in 2015. They provided information about our upcoming conferences, grant opportunities, ADDF ACCESS program and much more at the Society for Neuroscience Annual Meeting!

Alzheimer's Drug Discovery Foundation

16th International Conference on Alzheimer’s Drug Discovery

16th International Conference on Alzheimer’s Drug Discovery

October 4-6, 2015

 

Hyatt Regency
Jersey City, NJ

This annual conference brings together academic and industry scientists intent on accelerating the development of innovative treatments for Alzheimer’s disease and related dementias. The ADDF’s funded investigators and top-level scientists in the field will present on their current research progress and stimulate discussion. The conference offers ample opportunity for collaboration and partnering. For complete program and registration information, please visit our Conference Website.

Program Outline

Sunday, October 4, 2015
5:00–7:00 pm
On-Site Pre-Registration

Monday, October 5, 2015
8:00–9:20 am
Breakfast, Welcome & Plenary Lecture: Neuroinflammation: Mechanisms and Targets

9:30–12:30 pm
SESSION I: Apolipoproteins and Neuroinflammation

12:30–1:30 pm
Lunch, Poster and Exhibitor Session

1:35–5:10 pm
SESSION II: Neuroprotection, Mitochondrial Function and Synaptic Plasticity

5:20–7:00 pm
Networking Reception & Poster and Exhibitor Session

Tuesday, October 6, 2015
8:00–9:20 am
Breakfast, Welcome & Plenary Lecture: Progress and Future Directions in Tau Imaging

9:10 am–12:35 pm
SESSION III: Translatable Biomarkers to Accelerate Clinical Development

12:35–1:25 pm
Lunch, Poster and Exhibitor Session

1:25–4:20 pm
SESSION IV: TAU TDP-43, Progranulin and Protein Clearance

4:20–4:30 pm
Closing Remarks

Alzheimer's Drug Discovery Foundation

Hope Flies Health Series:
Research Connecting Alzheimer’s and Mitochondrial Disease

Research Connecting Alzheimer’s and Mitochondrial Disease

September 23, 2015

 


Webinar

Panelists:

  • Diana Shineman, Scientific Director of the Alzheimer’s Drug Discovery Foundation

  • Laura Stanley, Executive Director, Foundation for Mitochondrial Medicine

  • Cristy Balcells, RN, Executive Director, Mitoaction

  • Moderator: Darria Gillespie, MD MBA FACEP, SVP Clinical Strategy, Shareware

Learn more about the scientific connection and interest Alzheimer’s researchers have in mitochondria in this webinar. Hear about a specific research project the FMM and ADDF co-funded exploring this link. Understand similar challenges mitochondrial patients and Alzheimer’s patients face and how the day-to-day can be managed while treatment options are still being researched in the laboratory.

Q&A will follow with the panelists. Register online.

Alzheimer's Drug Discovery Foundation

AspenBrainLab

AspenBrainLab

July 25, 2015

 

Paepcke Auditorium
Aspen, Colorado

The third annual AspenBrainLab presents a provocative program of 12 brilliant short talks and meditations, all about the brain, that reframe what we know and what we think. Highlights include Dr. Howard Fillit on "Cracking the Alzheimer's Code," Walter Isaacson on "The Innovative Mind," William Moyers discussing his addiction and recovery, and six Tibetan Monks leading a chanting meditation.

Visit aspenbrainlab.com for the complete agenda and to register.

Alzheimer's Drug Discovery Foundation

Learning from Cancer to Advance Neurodegeneration Drug Discovery and Development

Learning from Cancer to Advance Neurodegeneration Drug Discovery and Development

June 11, 2015

 

The New York Academy of Sciences
New York, NY

Does having cancer decrease your risk of developing neurodegenerative diseases? Why do many cancer drug targets overlap with targets for neurodegeneration? This interdisciplinary meeting seeks to answer these questions and help attendees learn from the mechanistic insight and years of research on cancer biology to advance new therapeutic development for neurodegenerative diseases. Speakers will address how their research relates to both cancer and neurodegeneration and what we can learn about cell biology and function from these seemingly disparate diseases. Talks will also discuss cancer drug repurposing opportunities for Alzheimer’s and related dementias.

*Reception to follow.

For more information on the program, venue or to register please visit our Conference Website!

Alzheimer's Drug Discovery Foundation

Art Tour for Alzheimer’s

Art Tour for Alzheimer’s

May 19, 2015

5:30 – 7:00 pm

Ticket Price: $150

 


New York, NY

Join the Alzheimer’s Drug Discovery Foundation for cocktails and an exclusive guided tour of contemporary art galleries in New York’s Chelsea neighborhood. Hosted by ArtMuse founder Natasha Schlesinger, the Art Tour for Alzheimer’s is a unique opportunity to network with professionals passionate about Alzheimer’s while exploring the New York art scene with an award-winning art historian by your side.

RSVP to Jessica Cavanaugh at jcavanaugh@alzdiscovery.org or 212.901.8011 by Friday, May 1st. Spaces are limited.

Alzheimer's Drug Discovery Foundation

Ninth Annual
Connoisseur's Dinner

Ninth Annual Connoisseur’s Dinner

April 27, 2015

 

Sotheby's
New York, NY

On Monday, April 27, 2015, American theatre director, choreographer, film director and performer Susan Stroman hosted the Alzheimer’s Drug Discovery Foundation’s (ADDF) Ninth Annual Connoisseur’s Dinner at Sotheby’s in New York City.

With an audience of more than 230, Stroman spoke poignantly about the experience of losing her partner, director Steven Weisberg, to early-onset Alzheimer’s. “It’s devastating to watch someone disappear in front of you,” she said. “The ADDF gives us hope for a treatment one day.”

Co-chaired by Leonard A. Lauder of the Estée Lauder cosmetics family, the black-tie event featured fine wine, food and art. Also in attendance were Barbara and Donald Tober, Rose Marie Bravo, Paula Zahn and Meryl Comer.

Jamie Niven, Chairman, Sotheby’s Americas, hosted the evening’s lively “Fund a Scientist” auction, which gave guests the opportunity to support the science of three renowned Alzheimer’s researchers: Roberta Diaz Brinton, PhD, of the University of Southern California, and Joseph Foss, MD, and Mohamed Naguib, MD, of the Cleveland Clinic Foundation. The auction raised more than $1 million.

Later in the evening, Leonard A. Lauder presented the ADDF’s Founding Executive Director and Chief Science Officer, Howard Fillit, MD, with the Chairman’s Award for Lifetime Achievement. Dr. Fillit, a geriatrician, neuroscientist and leading expert in Alzheimer’s disease, was recognized for leading a life of compassion, innovation and leadership in Alzheimer’s disease.

Said Dr. Fillit, “Our ambition at ADDF is to create a world of older people who, despite some arthritis, heart disease, and even surviving a cancer, have the mental vitality to continue to contribute productively to society, to give back with wisdom because of decades of experience, and provide a legacy of love to families and friends.”


​VIEW PHOTOS FROM THE EVENT:

 

©Patrick McMullan

Alzheimer's Drug Discovery Foundation

Fifth Annual
Great Ladies Luncheon & Fashion Show

Fifth Annual Great Ladies Luncheon & Fashion Show

April 15, 2015

 

The Ritz-Carlton
Washington, DC

On Wednesday, April 15, 2015, renowned journalist and NPR host Diane Rehm welcomed guests to the Alzheimer’s Drug Discovery Foundation’s (ADDF) Fifth Annual Great Ladies Luncheon & Fashion Show at The Ritz-Carlton in Washington, DC.

Rehm, who has long used her public platform to raise awareness for Alzheimer’s disease, spoke eloquently about the need to increase support for drug discovery for Alzheimer’s. She also expressed hope for the future, noting that “there are hundreds of new, potentially disease-modifying drugs in the pipeline.”

The Great Ladies Luncheon & Fashion Show is the brainchild of Elise Lefkowitz, a well-known Washingtonian who lost her mother, Estelle Gelman, to Alzheimer’s disease. Elise and her husband Marc generously underwrite the fashion extravaganza on an annual basis.

In its fifth year, the Neiman Marcus-sponsored event featured a runway show with designs from Akris’s Fall/Winter 2015/16 Collection. The Swiss-luxury brand is immensely popular among the DC social set.

This year’s Luncheon & Fashion Show honored Emmy-Award winning journalist and author Meryl Comer. Comer’s New York Time’s bestseller, “Slow Dancing with a Stranger,” details her painful experience caring for her husband, who suffers from early-onset Alzheimer’s disease. 

Accepting her award, Comer said, “I fight for everyone who is well. I fight for all women because I want better options for them. And I fight because I don’t want my great grandchildren asking how their grandparent could forget them.”

The day began with a science symposium from the ADDF’s Founding Executive Director and Chief Science Officer, Howard Fillit, MD, who was joined by Roberta Diaz Brinton, PhD, of the University of Southern California. Entitled “Women and Alzheimer’s Disease,” the presentation explored the reasons women are more likely to develop Alzheimer’s disease.

With funding from the ADDF, Dr. Brinton is developing a drug, Allopregnanolone, which can reverse memory deficits in mice and restore normal cognitive function. During her presentation, Dr. Brinton noted that “it’s not the years women age [that increases their risk for Alzheimer’s] it’s the way that they age.”

The Great Ladies Luncheon & Fashion Show raised more than $229,000 to support Alzheimer's drug research.

Guests included:  Diane Rehm (Host and Executive Producer, “The Diane Rehm Show”), Meryl Comer (Emmy-Award Winning Journalist, Author of “Slowing Dancing with a Stranger,” and Alzheimer’s advocate), Elise Lefkowitz (Washington DC philanthropist), Roberta Diaz Brinton, PhD (Vanderveen Chair in Therapeutic Discovery and Development at the University of Southern California), Howard Fillit, MD (Founding Executive Director and Chief Science Officer, Alzheimer’s Drug Discovery Foundation), Ann B. Friedman (Director of Conservation International and wife of Thomas L. Friedman), Trish and George Vradenburg (Co-founders, UsAgainstAlzheimer’s and Washington DC philanthropists.)
 

VIEW PHOTOS FROM THE EVENT:


WATCH:
Women and Alzheimer’s Disease Presentation

EVENT SPONSORS


  • Estee Lauder Companies
  • Neiman Marcus
  • Kris
Alzheimer's Drug Discovery Foundation

Advisory Panel
Comparative Effectiveness

Comparative Effectiveness Advisory Panel

April 9-10, 2015

 

Debevoise and Plimpton LLP
New York, NY

The ADDF organized this panel of experts to discuss whether choices in the clinical care of existing conditions such as hypertension or diabetes could influence the risk of dementia and mild cognitive impairment (MCI). 

Among Alzheimer’s researchers, there is extensive study on whether medications approved for other diseases could have properties that help to protect the brain from Alzheimer’s disease. Most of that research focuses on repurposing (i.e., whether these drugs could also be used to treat Alzheimer’s disease). Another, less-studied question is whether the choice of one treatment versus another for common chronic conditions (e.g., diabetes, hypertension, and cardiovascular disease) could alter the risk for dementia. To influence physicians' choice of which medication to prescribe for chronic conditions, substantial evidence for the potential risk of future cognitive impairment will be needed. In this advisory panel, researchers focused on the best path forward to gather comparative effectiveness research to protect patients from dementia.

Alzheimer's Drug Discovery Foundation

9th Annual
Drug Discovery for Neurodegeneration Conference

9th Annual Drug Discovery for Neurodegeneration Conference

March 1-3, 2015

 

The Westgate Hotel
San Diego, CA

Designed as a comprehensive course on the drug discovery process, from target validation through to clinical development, the annual Drug Discovery for Neurodegeneration conference provides participants with the fundamental knowledge and resources to translate their research into new drugs to treat and prevent Alzheimer's disease and related neurodegenerative diseases.

Attendees from academia and industry will also learn from specific case studies examples and will have an opportunity to engage in interactive discussions on securing partnerships.

The program will include a focus on Alzheimer’s disease, Parkinson’s disease and Multiple Sclerosis.

More information, please visit our Conference Website.

Alzheimer's Drug Discovery Foundation

Alzheimer's Talk:
Roberta Diaz-Brinton, PhD

Alzheimer’s Talk: Roberta Diaz-Brinton, PhD

February 12, 2015

4:00-5:00 pm

 


Teleconference

Do you have questions about the Alzheimer’s risks facing women and the status of drugs that could help the aging brain to renew and repair itself? Dr. Roberta Diaz-Brinton—a leading Alzheimer’s researcher funded by the Alzheimer’s Drug Discovery Foundation—will be tackling these topics during an Alzheimer’s Talk hosted by UsAgainstAlzheimer’s on Thursday, February 12th  from 4:00 to 5:00 pm EST. 

This is a fantastic opportunity for anyone interested in learning more about Dr. Brinton’s cutting-edge research into the hormones and neurosteroids that defend and repair brain’s cells. Dr. Brinton will  also discuss the discovery and development of Allopregnanolone, a hormone derivative, which shows promise as a regenerative therapy for individuals with mild cognitive impairment and early-stage Alzheimer’s.

Reserve your spot today.

Alzheimer's Drug Discovery Foundation

Alzheimer's Talk:
Dr. Howard Fillit

Alzheimer’s Talk Featuring Dr. Howard Fillit

December 4, 2014

2:00-3:00 pm

 


Teleconference

Do you have questions about Alzheimer’s prevention, drug discovery and/or research progress? On Thursday, December 4, 2014 from 2:00 to 3:00 PM EST Dr. Howard Fillit will be tackling these topics during an Alzheimer’s Talks call hosted by USAgainstAlzheimer’s.

The best part: you don’t have to be in the New York area to attend! You can:

The call is a great learning opportunity for anyone interested in hearing more about these timely topics.

Alzheimer's Drug Discovery Foundation

ADDF to Exhibit at
The Society for Neuroscience Annual Meeting

ADDF to Exhibit at the Society for Neuroscience Annual Meeting

November 15-19, 2014

 

Walter E. Washington Convention Center
Washington, DC

Come visit the ADDF team at booth 3305! Learn more about our upcoming conferences, grant opportunities, our newly launched ADDF ACCESS program and much more!

Alzheimer's Drug Discovery Foundation

Fifth Annual
Fall Symposium & Luncheon

Fifth Annual Fall Symposium & Luncheon

November 3, 2014

 

The Pierre
New York, NY

On November 3, 2014, former model and restaurateur B. Smith was honored by the Alzheimer’s Drug Discovery Foundation (ADDF) at its Fifth Annual Fall Symposium & Luncheon “Hope on the Horizon” at The Pierre in New York City. Smith, who publicly revealed her early-onset Alzheimer’s diagnosis in June, was presented with The Charles Evans Award at the Luncheon for using her powerful platform to promote public awareness and raise critical funds to combat Alzheimer’s disease.

Smith graciously accepted the award in a purple dress, the official color of National Alzheimer’s Disease Awareness Month, with her husband and long-time business partner Dan Gasby by her side. During her speech, Smith became overwhelmed with emotion and her husband stepped in to finish, saying, “Sweetie prepared a speech, but we’ll just speak from the heart quickly.” Gasby went on to say that instead of starting their own foundation, they decided to support ADDF because, “We wanted to go where we knew the dollars were going to be used most judiciously and with the greatest amount of intellectual capabilities.” 

Following the award presentation, Emmy Award-winning journalist Paula Zahn conducted an informative onstage interview with Dr. Howard Fillit, the ADDF’s Founding Executive Director and Chief Science Officer, and Dr. Michael W. Weiner, a Professor of Medicine, Radiology, Psychiatry and Neurology at the University of California, San Francisco; Principal Investigator of the Alzheimer’s Disease Neuroimaging Initiative (ADNI).

Leonard A. Lauder, the ADDF's Co-Founder and Co-Chairman, closed out the event by thanking guests for coming and telling them, “This is a passion. And it’s passion and drive that get things done. And we’ll get this done for you!”

The event began with a morning presentation from Dr. Fillit, entitled “Conquering Alzheimer’s Disease: A Progress Report.” Dr. Fillit shared an insider’s view of the latest news in the field of Alzheimer’s drug development and discussed aging and prevention, and what individuals can do today to protect their lifelong cognitive vitality.  

The event raised more than $860,000 to support Alzheimer's drug research and related programs. 

Download a copy of Dr. Howard Fillit's presentation,  "Conquering Alzheimer's Disease: A Progress Report."

Alzheimer's Drug Discovery Foundation

2014 New York City Marathon

2014 New York City Marathon

November 2, 2014

 


New York, NY

For Fans

Meet us in Central Park on November 2, 2014 at 9:40 am as we cheer on the Runners for Alzheimer’s Research team in the TCS New York City Marathon. All funds raised in support of the team will benefit the Alzheimer’s Drug Discovery Foundation (ADDF).

Make a donation to support the Runners for Alzheimer's Research team.

For Runners

Interested in joining the team? All runners who have secured their own entry into the marathon can call (212) 901-8011 or email Jessica Cavanaugh to request a spot on the Runner’s for Alzheimer’s Research team. Team runners can attend our post-marathon reception free of charge.

Download the Runners for Alzheimer's Research information packet for more information.

Invite your friends and family to join the Runners For Alzheimer's Research with our outreach letter. 

Alzheimer's Drug Discovery Foundation

15th International
Conference on Alzheimer's Drug Discovery

15th International Conference on Alzheimer’s Drug Discovery

September 8-9, 2014

 

Hyatt Regency
Jersey City, NJ

This annual conference brings together academic and industry scientists intent on accelerating the development of innovative treatments for Alzheimer’s disease and related dementias. The ADDF’s funded investigators and top-level scientists in the field will present on their current research progress and stimulate discussion. The conference offers ample opportunity for collaboration and partnering.

For more information, please visit our Conference Website.

Alzheimer's Drug Discovery Foundation

The Biology of Aging:
Novel Drug Targets for Neurodegenerative Disease

The Biology of Aging: Novel Drug Targets for Neurodegenerative Disease

May 9, 2014

8:00 am - 4:00 pm

 

The New York Academy of Sciences
New York, NY

Age is the greatest risk factor for Alzheimer's disease. Key pathways within the biology of aging may represent important targets to develop novel and effective disease-modifying drugs to treat, delay, or prevent Alzheimer's and other age-related neurodegenerative diseases. In this 1-day conference, experts will present major recent advances in aging biology that represent important opportunities for drug discovery for Alzheimer's and other age-related neurodegenerative diseases. The first half of the day will focus on the basic biology of aging-related pathways, with one session on major circuits and a second session on novel targets and pathways. The second half of the day will focus on drug development programs for neurodegenerative disease based on targets identified from aging biology, including recent scientific advances in the science of autophagy, mitochondrial health, inflammation, and protein homeostasis.

*Reception to follow.

For more information on the program, venue or to register please visit our Conference Website

Alzheimer's Drug Discovery Foundation

Eighth Annual
Connoisseur's Dinner

Eighth Annual Connoisseur’s Dinner

May 1, 2014

 

Sotheby's
New York, NY

The Alzheimer's Drug Discovery Foundation (ADDF) hosted its Eighth Annual Connoisseur’s Dinner, “To Live is to Think,” on Thursday, May 1, 2014 at Sotheby’s in New York City. Leonard A. Lauder, Co-Chairman of the ADDF, was honored with the evening's Chairman's Award and Norah O’Donnell, co-anchor of CBS This Morning, hosted the event. The dinner brought in more than $3.7 million to fund research in Alzheimer's drug development, including nearly $1.2 million to "Fund a Scientist" during a live auction led by Sotheby's own Jamie Niven. Proceeds from the auction went to support the work of Dr. Jeffrey Cummings, who will investigate rasagiline, an FDA-approved treatment for Parkinson’s disease with the potential to be the first drug to slow the course of Alzheimer’s disease.

EVENT SPONSORS


  • Estee Lauder Companies
  • Colliers International
  • First Republic Bank
  • Macy's Inc
  • EY
  • Sotheby's
Alzheimer's Drug Discovery Foundation

Fourth Annual
Great Ladies Luncheon & Fashion Show

4th Annual Great Ladies Luncheon and Fashion Show

April 1, 2014

10:45 am

 

The Ritz-Carlton
Washington, DC

The Alzheimer's Drug Discovery Foundation hosted its 4th Annual Great Ladies Luncheon and Fashion Show on Tuesday, April 1, 2014 at The Ritz-Carlton in Washington, DC. The Luncheon, co-chaired by Leonard A. Lauder and Elise and Marc Lefkowitz, was held in partnership with Saks Fifth Avenue. The day commenced at 10:45 a.m. with an Alzheimer’s drug discovery update hosted by NBC’s Chief Foreign Affairs Correspondent, Andrea Mitchell and presented by Howard Fillit, MD, Executive Director and Chief Science Officer. At 12 noon, guests enjoyed lunch and a runway show and special appearance by Erdem. Kathleen Matthews, Chief Communications and Public Affairs Officer for Marriott International, emceed the Luncheon and Pat Summitt, former head coach of the University of Tennessee Lady Volunteer basketball team, received the Great Ladies Award. The event raised over $239,000 for Alzheimer's disease research and related programs.


Pat Summitt with Nancy Corzine. Photo by Tony Powell.

EVENT SPONSORS


  • Saks Fifth Avenue
  • Estes Lauder Companies
  • Erdem
Alzheimer's Drug Discovery Foundation

8th Annual
Drug Discovery for Neurodegeneration Disease

8th Annual Drug Discovery for Neurodegeneration Conference

February 2-4, 2014

 

Miami Beach Resort
Miami, FL

The 8th Annual Drug Discovery for Neurodegeneration Conference is designed as a comprehensive course on the drug discovery process, from target validation through to clinical development, the annual Drug Discovery for Neurodegeneration conference provides participants with the fundamental knowledge and resources to translate their research into new drugs to treat and prevent Alzheimer's disease and related neurodegenerative diseases.

Attendees from academia and industry will also learn from specific case studies examples and will have an opportunity to engage in interactive discussions on securing partnerships.

The program will include a focus on Alzheimer’s disease, Parkinson’s disease and Multiple Sclerosis.

More information, please visit our Conference Website.

Alzheimer's Drug Discovery Foundation

Anya Hindmarch Reception to Benefit ADDF

Anya Hindmarch Reception to Benefit ADDF

November 14, 2013

 

Anya Hindmarch Flagship Store
New York, NY

Anya Hindmarch and Jean H. Pearman hosted a private shopping evening at the Anya Hindmarch Flagship Store, 795 Madison Avenue, on November 14, 2013 to benefit the Alzheimer's Drug Discovery Foundation.

Click here to view the invitation

Alzheimer's Drug Discovery Foundation

ADDF to Exhibit at
The Society for Neuroscience Annual Meeting

ADDF to Exhibit at the Society for Neuroscience Annual Meeting

November 9-13, 2013

 

San Diego Convention Center
San Diego, CA

Come visit the ADDF team at booth number 4004. Learn more about our upcoming conferences, grant opportunities, our newly launched ADDF ACCESS program and much more!

Alzheimer's Drug Discovery Foundation

Bonnie Star Jewelry Show to Benefit ADDF

Bonnie Star Jewelry Show to Benefit ADDF

November 7, 2013

6:00-8:00 pm

 

Saks Fifth Avenue
New York, NY

Saks Fifth Avenue, along with Darren Star and Elise Gelman Lefkowitz, invite you to meet jewelry designer Bonnie Star and celebrate her new Fall 2013 Collection Thursday, November 7 from 6 p.m. to 8 p.m.

10% of the evening’s proceeds will be donated to the ADDF.

Jewelry Gallery on One, Fifth Avenue and 50th Street.

Kindly reply to bonniestar@saks.com

Click here to view the invitation

Alzheimer's Drug Discovery Foundation

ADDF Professionals Night Out:
Conquering Alzheimer's Through Drug Discovery

ADDF Professionals Night Out: Conquering Alzheimer’s Through Drug Discovery

September 26, 2013

 

GoldBar
New York, NY

The Professionals Steering Committee of the Alzheimer's Drug Discovery Foundation hosted an exclusive evening of music, a silent auction and cocktails on Thursday, September 26, 2013.

The evening raised $2,200 for Alzheimer's disease research and related programs.

Hosted by:

Thomas Haug, Chris Johnson, Kevin Kitt, Drew Gilbert, Courtney Fischer, Jayme Rubright, Carrie Tracy, Vina Orden, Aileen Schruth, Ryan Ward, Brendan Ward and Julia Lovallo.

Alzheimer's Drug Discovery Foundation

4th Annual Fall Luncheon & Symposium
Hope on the Horizon: New Drugs for Alzheimer's Disease

4th Annual Fall Luncheon & Symposium: Hope on the Horizon

September 17, 2013

 

The Pierre
New York, NY

The ADDF held its 4th Annual Fall Luncheon & Symposium: Hope on the Horizon: New Drugs for Alzheimer’s Disease at The Pierre in New York City on September 17, 2013. The luncheon raised more than $759,000 for Alzheimer’s drug research and related programs.

Bonnie Pfeifer Evans and Alice Shure presented the Charles Evans Award to Liz and Randal Sandler. The Sandlers announced a $1 million challenge grant, calling on other supporters to make a pledge—at any level—to help fund clinical trials.  The Luncheon concluded with a lively and insightful conversation between Dr. Howard Fillit, Executive Director and Chief Science Officer of ADDF, and Dr. Jeffrey L. Cummings, Director of the Cleveland Clinic’s Lou Ruvo Center for Brain Health, moderated by Paula Zahn.


EVENT SPONSORS


  • Estee Lauder
  • Flexjet Bombardier
  • Staples

LEADERSHIP


Executive Chair

  • Leonard Lauder

Co-Chairs

  • Nancy Corzine
  • The Estée Lauder Companies Inc.
  • Barbara and Raymond Dalio
  • Flexjet
  • Nancy and Mel Goodes
  • Dan Lufkin, The Peter Jay Sharp Foundation
  • Anne and Andrew Moller
  • Emily C. Rose
  • Staples
  • Tishman Speyer Properties, LP

Honorary Chairs

  • Bonnie Pfeifer Evans
  • Alice Shure
  • Joan Sutton Straus
Alzheimer's Drug Discovery Foundation

14th International
Conference on Alzheimer's Drug Discovery

14th International Conference on Alzheimer’s Drug Discovery

September 8-10, 2013

 

Hyatt Regency
Jersey City, NJ

This annual conference brings together academic and industry scientists intent on accelerating the development of innovative treatments for Alzheimer’s disease and related dementias. The ADDF’s funded investigators and top-level scientists in the field will present on their current research progress and stimulate discussion. The conference offers ample opportunity for collaboration and partnering.

For more information, please visit our Conference Website.

Alzheimer's Drug Discovery Foundation

Music Cures Benefit Concert

Music Cures Benefit Concert

July 25, 2013

 

Cutting Room
New York, NY

The ADDF and the Kaneff Foundation held their inaugural Music Cures benefit concert at the Cutting Room on July 25. The Young Presidents performed along with Ivan Neville, Corey Glover, Blondie Chaplin, and Anton Fig. Victoria Ghost, featuring Ashley and Shannon Campbell, children of legendary singer/songwriter Glen Campbell, played the opening performance. 

Sponsored by the Kaneff Foundation

Alzheimer's Drug Discovery Foundation

Hope on the Horizon:
Atlanta Luncheon + Symposium

Hope on the Horizon: Atlanta Luncheon + Symposium

May 16, 2013

10:45 am – 2:30 pm

 

Piedmont Driving Club
Atlanta, GA

The ADDF held the Hope on the Horizon Atlanta Luncheon & Symposium on Thursday, May 16 at the Piedmont Driving Club in Atlanta, Georgia. Co-Chaired by Leonard A. Lauder and Mary Rose Taylor, this inaugural event was held in partnership with the Alzheimer’s Society of Atlanta and honored internationally renowned designer Dan Carithers. Jaye Watson from NBC 11 Alive News will act as Master of Ceremonies. 100% of event proceeds went to Emory University’s Alzheimer’s Disease Research Center (ADRC) led by Allan Levey, MD, PhD.

Alzheimer's Drug Discovery Foundation

Translating Natural Products into Drugs for Alzheimer’s and Neurodegenerative Disease

Translating Natural Products into Drugs for Alzheimer’s and Neurodegenerative Disease

May 6, 2013

 

The New York Academy of Sciences
New York, NY

Historically, natural products have been a highly successful source for the development of new drugs. Alzheimer's and other neurodegenerative diseases are fraught with challenging drug targets that may benefit from the novel chemistries present in natural products. In addition, technological advances may present new opportunities for drug discovery based on natural product leads. This conference will present an overview of drug discovery from natural products, including novel approaches and technologies, and promising Alzheimer's drug discovery programs that originated from natural products. To view the ebriefing.

Alzheimer's Drug Discovery Foundation

Seventh Annual
Connoisseur's Dinner

7th Annual Connoisseur’s Dinner

May 2, 2013

 

Sotheby's
New York, NY

The ADDF held its Seventh Annual Connoisseur’s Dinner, “To Live is to Think,” on Thursday, May 2, 2013 at Sotheby’s in New York City.  Co-Chairs were Nancy Corzine, Sir Evelyn and Lady Lynn Forester de Rothschild, Nancy and Melvin R. Goodes, Leonard A. Lauder, Jo Carole and Ronald S. Lauder, and Liz and Randal Sandler. The Chairman’s Award was presented to Paula Zahn, whose efforts have made a substantial difference in raising awareness and promoting expanded funding for Alzheimer’s disease drug research. The Fund a Scientist auction was the centerpiece of the evening, and Chairman of Sotheby’s, Americas Jamie Niven helped raise funds for The ADDF/Belfer ApoE Therapeutics Innovation Program.

Alzheimer's Drug Discovery Foundation

Third Annual
Great Ladies Luncheon & Fashion Show

Third Annual Great Ladies Luncheon & Fashion Show

April 11, 2013

10:45 am

 

Saks Fifth Avenue
Chevy Chase, MD

The ADDF hosted its Third Annual Great Ladies Luncheon and Fashion Show on Thursday, April 11. The Luncheon, co-chaired by Leonard A. Lauder and Elise and Marc Lefkowitz, and in collaboration with Saks Fifth Avenue, was held at Saks Fifth Avenue in Chevy Chase, MD in a tent inspired by Fashion Week runway shows. The day commenced at 10:45 am with an Alzheimer’s drug discovery update presented by Howard Fillit, MD. At 12 pm, guests enjoyed lunch and a runway show and special appearance by famed designer Jason Wu. Barbara Harrison acted as Master of Ceremonies and Sharon Percy Rockefeller received the Great Ladies Award.

LEADERSHIP


Executive Co-Chairs

Leonard A. Lauder
Elise and Marc Lefkowitz
Ronald L. Frasch

Vice Chairs

Nancy Corzine
David Deckelbaum
Louann Deckelbaum
Faith and Warren Diamond
The Estée Lauder Companies Inc.
Omega Capital Enterprises, LLC
Thomas Pheasant

Alzheimer's Drug Discovery Foundation

Vero Beach Benefit

Vero Beach Benefit

March 12, 2013

 

Riverside Theatre
Vero Beach, FL

Leonard A. Lauder and Nancy and Mel Goodes hosted an evening benefitting the ADDF that raised more than $200,000. The event began with a VIP reception at the home of Nancy and Mel Goodes. After dinner, guests convened at Riverside Theatre for an exclusive preview of the work-in-progress documentary, UNTITLED: Glen Campbell Documentary, followed by Q&A with filmmakers James Keach and Trevor Albert. The highlight of the evening was a performance by Ashley and Shannon Campbell of Victoria Ghost, who were joined onstage by their father, legendary singer and guitarist Glen Campbell.

Alzheimer's Drug Discovery Foundation

7th Annual
Drug Discovery for Neurodegeneration Conference

7th Annual Drug Discovery for Neurodegeneration Conference

February 10-12, 2013

 

Hyatt Fisherman's Wharf
San Francisco, CA

The 7th Annual Drug Discovery for Neurodegeneration Conference course is designed to advance the development of new drugs for neurodegenerative diseases by educating scientists on the principles and practice of drug discovery, including topics such as high throughput screening, lead optimization, preclinical proof-of-concept, and IND enabling and regulator issues. The program will focus on Alzheimer’s disease, Parkinson’s disease, Amyotrophic Lateral Sclerosis and Multiple Sclerosis.

For more information, please visit our Conference Website.

Alzheimer's Drug Discovery Foundation

ADDF to Exhibit at the Society for Neuroscience Annual Meeting

ADDF to Exhibit at the Society for Neuroscience Annual Meeting

October 13-17, 2012

 


New Orleans, LA

Alzheimer's Drug Discovery Foundation

13th International Conference on Alzheimer’s Drug Discovery

13th International Conference on Alzheimer’s Drug Discovery

September 10-11, 2012

 


Jersey City, NJ

This annual conference brings together academic and industry scientists intent on accelerating the development of innovative treatments for Alzheimer’s disease and related dementias. The ADDF’s funded investigators and top-level scientists in the field will present on their current research progress and stimulate discussion. The conference offers ample opportunity for collaboration and partnering. 

For more information, please visit our Conference Website

Alzheimer's Drug Discovery Foundation

Targeting Synaptic Dysfunction in Alzheimer’s Disease

Targeting Synaptic Dysfunction in Alzheimer’s Disease

May 18, 2012

 


New York City, NY

For more information, please visit our Conference Website

Alzheimer's Drug Discovery Foundation

Targeting the Vasculature in Alzheimer’s Disease and Vascular Cognitive Impairment

Targeting the Vasculature in Alzheimer’s Disease and Vascular Cognitive Impairment

May 6, 2012

 


New York City, NY

For more information, please visit our Conference Website

Alzheimer's Drug Discovery Foundation

6th Drug Discovery for Neurodegeneration: An Intensive Course on Translating Research into Drugs

6th Drug Discovery for Neurodegeneration: An Intensive Course on Translating Research into Drugs

February 12-14, 2012

 


New York City, NY

The 6th Annual Drug Discovery for Neurodegeneration Conference course is designed to advance the development of new drugs for neurodegenerative diseases by educating scientists on the principles and practice of drug discovery, including topics such as high throughput screening, lead optimization, preclinical proof-of-concept, and IND enabling and regulator issues. The program will focus on Alzheimer’s disease, Parkinson’s disease, Amyotrophic Lateral Sclerosis and Multiple Sclerosis.

For more information, please visit our Conference Website

Alzheimer's Drug Discovery Foundation

12th International Conference on Alzheimer’s Drug Discovery

12th International Conference on Alzheimer’s Drug Discovery

September 26-27, 2011

 


Jersey City, NJ

This global conference was designed to accelerate the development of innovative treatments for Alzheimer’s disease (AD), related dementias and cognitive aging. The ADDF’s funded investigators and top level scientists in the field presented on their current research progress and stimulated discussion.  The conference provided ample opportunity for scientists to network, form collaborations, and share information and resources. The meeting attracted 135 key stakeholders from the pharmaceutical, biotechnology, government and academic communities.

For more information, please visit our Conference Website

Alzheimer's Drug Discovery Foundation

Targeting Synaptic Dysfunction in Alzheimer’s Disease

Targeting Synaptic Dysfunction in Alzheimer’s Disease

May 18, 2011

 


New York, NY

Optimal functioning of neural networks is critical to the complex cognitive processes of memory, language, emotion, and reasoning that deteriorate in Alzheimer's disease. Understanding the mechanisms by which synaptic connections are formed and create neural networks is crucial to developing new drugs to protect and maintain neuronal function and connectivity. This conference provided an overview of the process of synaptic plasticity in normal aging and in neurodegenerative disease, and outline therapeutic strategies to preserve vital neural connections.

 

Learn More

Alzheimer's Drug Discovery Foundation

5th Drug Discovery for Neurodegeneration: An Intensive Course on Translating Research into Drugs

5th Drug Discovery for Neurodegeneration: An Intensive Course on Translating Research into Drugs

February 6-8, 2011

 


San Diego, CA

Designed as a comprehensive course, this annual conference provided participants with the fundamental knowledge and resources, as well as the associated barriers, and challenges on creating new drugs to treat and prevent neurodegenerative disease. Case studies on Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis were included in the discussions.  The meeting attracted 142 academic, industry, and government scientists from around the world. The ADDF developed this conference in collaboration with the National Institutes of Health (NIH).

Click here to view a webcasts of the conference proceedings.  There is also an interactive Drug Discovery Tutorial based of the conference, which can be accessed here.

For more information, please visit our Conference Website

Alzheimer's Drug Discovery Foundation

International Pharmaco-Economic Conference on Alzheimer’s Disease

International Pharmaco-Economic Conference on Alzheimer’s Disease

February 3-4, 2011

 


London, UK

The ADDF co-developed and organized the 6th International Conference on Pharmacoeconomics on Alzheimer’s Disease (IPECAD) meeting with the Karolinska Institutet, Stockholm. IPECAD is the only conference that exclusively addresses issues related to the economic evaluation of drug treatments for Alzheimer’s disease. It brings together leading experts and opinion leaders from academia, regulatory bodies and the pharmaceutical industry. Approximately 75 health economists and scientists from around the world attended this meeting. 

For more information, please visit our Conference Website

Alzheimer's Drug Discovery Foundation

Feeding the Pipeline: Novel Targets for Alzheimer’s Drug Discovery

Feeding the Pipeline: Novel Targets for Alzheimer’s Drug Discovery

November 3, 2010

 


Toulouse, France

This one-day symposium focused on European biotechnology companies conducting early-stage high risk research for Alzheimer’s disease that complement approaches in advanced clinical trials. This satellite meeting was held in conjunction with the 3rd Clinical Trials for Alzheimer’s Disease (CTAD) conference. The symposium attracted approximately 250 attendees from all over the world and all levels of academia, government, and industry.

For more information, please visit our Conference Website

Alzheimer's Drug Discovery Foundation

11th Annual International Conference on Alzheimer’s Drug Discovery

11th Annual International Conference on Alzheimer’s Drug Discovery

September 27-28, 2010

 


Jersey City, NJ

This global conference was designed to help accelerate the development of innovative treatments for Alzheimer’s disease, related dementias, and cognitive aging. The ADDF’s funded investigators and top level scientists in the field presented on their current research progress and stimulated discussion. The conference provided ample opportunity for scientists to network, form collaborations, and share information and resources. The meeting attracted 155 key stakeholders from the pharmaceutical, biotechnology, government and academic communities.

For more information, please visit our Conference Website

Alzheimer's Drug Discovery Foundation

Mitochondrial Function as a Therapeutic Target for Alzheimer’s Disease

Mitochondrial Function as a Therapeutic Target for Alzheimer’s Disease

May 13, 2010

 


New York City, NY

Growing evidence indicates that mitochondrial dysfunction is one of the key intracellular mechanisms associated with the pathogenesis of Alzheimer's disease. The role of mitochondria as regulators of energy metabolism and cell death pathways makes it crucial to neuronal cell survival or death. The goal of this conference was to critically examine potential drug therapeutics for mitochondrial dysfunction in Alzheimer’s disease. Recent findings from basic, clinical, and translational research were presented in a forum designed to stimulate discussion of mitochondrial function and its relationship to age-related neurodegenerative disease, in particular, Alzheimer’s disease and its treatment.

For more information, please visit our Conference Website

Alzheimer's Drug Discovery Foundation

4th Drug Discovery for Neurodegeneration: An Intensive Course on Translating Research into Drugs

4th Drug Discovery for Neurodegeneration: An Intensive Course on Translating Research into Drugs

February 1-2, 2010

 


Houston, TX

Designed as a comprehensive course, this annual conference provided participants with the fundamental knowledge and resources, as well as the associated barriers and challenges on creating new drugs to treat and prevent neurodegenerative disease. Case studies on Alzheimer’s disease, Parkinson’s disease, Amyotrophic Lateral Sclerosis and Multiple Sclerosis were included in the discussions. The meeting attracted 92 leading academic, industry and government scientists from around the world. The ADDF developed this conference in collaboration with the National Institutes of Health (NIH). Click here to view a webcast of the conference proceedings. 

For more information, please visit our Conference Website

Alzheimer's Drug Discovery Foundation

9th International Conference on Alzheimer’s Disease Drug Discovery

9th International Conference on Alzheimer’s Disease Drug Discovery

October 6-7, 2008

 


New York, NY

This global conference was designed to help accelerate the development of innovative treatments for Alzheimer’s disease, related dementias, and cognitive aging. The ADDF’s funded investigators and top level scientists in the field presented on their current research progress and stimulated discussion. The conference provided ample opportunity for scientists to network, form collaborations, and share information and resources. The meeting attracted 156 key stakeholders from the pharmaceutical, biotechnology, government and academic communities.

For more information, please visit our Conference Website

Alzheimer's Drug Discovery Foundation

10th International Conference on Alzheimer’s Drug Discovery

10th International Conference on Alzheimer’s Drug Discovery

September 14-15, 2009

 


Jersey City, NJ

This global conference was designed to help accelerate the development of innovative treatments for Alzheimer’s disease, related dementias, and cognitive aging. The ADDF’s funded investigators and top level scientists in the field presented on their current research progress and stimulated discussion. The conference provided ample opportunity for scientists to network, form collaborations, and share information and resources. The meeting attracted 113 key stakeholders from the pharmaceutical, biotechnology, government and academic communities.

For more information, please visit our Conference Website

Alzheimer's Drug Discovery Foundation

Therapeutics for Cognitive Aging

Therapeutics for Cognitive Aging

May 15, 2009

 


New York City, NY

This one day symposium focused on an issue of great importance to an aging society – the development of novel therapies for cognitive decline across the lifespan of humans. This meeting convened prominent basic and clinical scientists who study the cognitive and neurobiological aspects of aging and its consequences for cognition. Speakers covered three main areas: the definition of cognitive aging, the underlying neurobiology of cognitive aging, and issues in the development of potential new therapies for cognitive aging including the use of biomarkers, drug therapy and a discussion of related regulatory issues.

 

For more information, please visit our Conference Website

Alzheimer's Drug Discovery Foundation

3rd Drug Discovery for Neurodegeneration: An Intensive Course on Translating Research into Drugs

3rd Drug Discovery for Neurodegeneration: An Intensive Course on Translating Research into Drugs

February 2-3, 2009

 


Washington, DC

Designed as a comprehensive course, this annual conference provided participants with the fundamental knowledge and resources, as well as the associated barriers and challenges on creating new drugs to treat and prevent neurodegenerative disease. Case studies on Alzheimer’s disease, Parkinson’s disease, Amyotrophic Lateral Sclerosis, Huntington’s disease and Multiple Sclerosis were included in the discussions. The meeting attracted 140 leading academic, industry and government scientists from around the world. The ADDF developed this conference in collaboration with the National Institutes of Health (NIH). 

For more information, please visit our Conference Website

Alzheimer's Drug Discovery Foundation

2nd Drug Discovery for Neurodegeneration: An Intensive Course on Translating Research into Drugs

2nd Drug Discovery for Neurodegeneration: An Intensive Course on Translating Research into Drugs

February 4-5, 2008

 


Washington, DC

Designed as a comprehensive course, this annual conference provided participants with the fundamental knowledge and resources, as well as the associated barriers and challenges on creating new drugs to treat and prevent neurodegenerative disease. Case studies on Alzheimer’s disease, Parkinson’s disease, Amyotrophic Lateral Sclerosis, Huntington’s disease, and Multiple Sclerosis were included in the discussions. The meeting attracted 155 leading academic, industry and government scientists from around the world. The ADDF developed this conference in collaboration with the National Institutes of Health (NIH). 

For more information, please visit our Conference Website

Alzheimer's Drug Discovery Foundation

8th International Conference on Alzheimer’s Disease Drug Discovery

8th International Conference on Alzheimer’s Disease Drug Discovery

October 15-16, 2007

 


New York, NY

This global conference was designed to help accelerate the development of innovative treatments for Alzheimer’s disease, related dementias and cognitive aging. The ADDF’s funded investigators and top level scientists in the field presented on their current research progress and stimulated discussion. The conference provided ample opportunity for scientists to network, form collaborations, and share information and resources. The meeting attracted 139 key stakeholders from the pharmaceutical, biotechnology, government and academic communities.

For more information, please visit our Conference Website

Alzheimer's Drug Discovery Foundation

1st Drug Discovery for Neurodegeneration: An Intensive Course on Translating Research into Drugs

1st Drug Discovery for Neurodegeneration: An Intensive Course on Translating Research into Drugs

February 5-6, 2007

 


New York, NY

Designed as a comprehensive course, this annual conference provided participants with the fundamental knowledge and resources, as well as the associated barriers and challenges on creating new drugs to treat and prevent neurodegenerative disease. The meeting attracted approximately 135 leading academic, industry and government scientists from around the world. The ADDF developed this conference in collaboration with the National Institutes of Health (NIH).